UNICREDIT BANK/CALL/ASTRAZENECA/12500/0.1/19.03.25 | Real-time BOERSE MUENCHEN 03:46:42 2024-07-11 am EDT | ||
| 1.07 EUR | +1.90% |
|
| Current month | -19.85% | ||
| 1 month | -30.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.07 | +1.90% |
| 24-07-10 | 1.05 | +3.96% |
| 24-07-09 | 1.01 | -4.72% |
| 24-07-08 | 1.06 | -1.85% |
| 24-07-05 | 1.08 | -4.42% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 03:46 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD4W6S |
| ISIN | DE000HD4W6S2 |
| Date issued | 2024-04-22 |
| Strike | 12,500 p |
| Maturity | 2025-03-19 (252 Days) |
| Parity | 10 : 1 |
| Emission price | 0.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.53 € |
|---|---|
| Lowest since issue | 0.72 € |
| Spread | 0.01 € |
| Spread % | 0.93% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.1
USD
Average target price
175.3
USD
Spread / Average Target
+13.01%
- Stock Market
- Warrants
- Warrant
